EGFR Exon 20 Mutation clinical trials at University of California Health

• A Study of CLN-081 in Patients With Non-Small Cell Lung Cancer

  Sorry, not currently recruiting here

  CLN-081-101 is a Phase 1/2a, open label, multi-center study of CLN-081 in patients with NSCLC (non small cell lung cancer) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

  at UC Davis

Last updated: March 18, 2021